e-ISSN: Pending
Failed Experiment ReportOpen accessTherapeutics. Pharmacology

Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial

Girish Parthan; Shobhit Bhansali; Anura V. Kurpad; Rama Walia; Kishor Bhat; Anil Bhansali · 2018 · BMC Pharmacology and Toxicology

WASTE classifies this as Failed Experiment Report · AI classification, approximate

An experimental approach did not work as intended — learn what to avoid before investing the same effort.

Abstract

Abstract Background Dipeptidyl peptidase 4 (DPP4) inhibitors improve glycemic control by promoting GLP1-mediated glucose-dependent insulin secretion and suppression of glucagon. Sitagliptin and vildagliptin have been shown to improve insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). However, these patients had uncontrolled blood glucose at inclusion; therefore, the improvement in insulin sensitivity observed in these studies could be attributed to the drug per se and/or reduction in glucotoxicity. This study examines the effect of linagliptin on insulin sensitivity and β-ce

Abstract by Girish Parthan; Shobhit Bhansali; Anura V. Kurpad; Rama Walia; Kishor Bhat; Anil Bhansali, BMC Pharmacology and Toxicology (2018) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1186/s40360-018-0228-z